Zevra Therapeutics, Inc. ZVRA Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $62.41M+84.7% | $33.79M-21.5% | $43.05M-34.2% | $65.47M-41.7% | ||
| $128.61M+260% | $35.71M— | $0-100% | $481K— | ||
| $23.26M+121% | $10.51M-39.5% | $17.38M+109% | $8.3M+443% | ||
| $13M-69.3% | $42.38M+269% | $11.49M+461% | $2.05M— | ||
| $223.01M+159% | $86.03M-1.0% | $86.94M-6.4% | $92.83M-19.3% | ||
| $489K+37.4% | $356K-51.6% | $736K-7.3% | $794K-10.2% | ||
| $4.7M0.0% | $4.7M0.0% | $4.7M— | $0— | ||
| $6.42M-90.7% | $68.99M-0.3% | $69.23M— | $0— | ||
| $284.73M+59.8% | $178.13M+3.4% | $172.33M+49.4% | $115.34M-13.2% | ||
| $11.6M-54.4% | $25.46M-10.4% | $28.4M+360% | $6.17M+103% | ||
| $39.28M+15.3% | $34.07M-53.8% | $73.72M+513% | $12.02M+184% | ||
| $61.93M+4.1% | $59.5M+1,075% | $5.07M— | $0— | ||
| $11.12M-92.0% | $138.46M+25.3% | $110.46M+175% | $40.22M+591% | ||
| $6K+20.0% | $5K+25.0% | $4K+33.3% | $3K-25.0% | ||
| -$422.06M+16.5% | -$505.29M-26.4% | -$399.78M-13.0% | -$353.73M-32.5% | ||
| $154.66M+290% | $39.67M-35.9% | $61.86M-17.6% | $75.12M-26.1% | ||
| $284.73M+59.8% | $178.13M+3.4% | $172.33M+49.4% | $115.34M-13.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Zevra Therapeutics, Inc.'s total assets?
- Zevra Therapeutics, Inc. (ZVRA) holds $278.6M in total assets, up 61.3% year over year.
- How much debt does Zevra Therapeutics, Inc. have?
- Zevra Therapeutics, Inc. carries $1.1M in total debt against $205.8M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Zevra Therapeutics, Inc. have?
- Zevra Therapeutics, Inc. holds $95.6M in cash and equivalents.
- Can Zevra Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 4.89 — current assets exceed current liabilities.
- Where does Zevra Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
